Answers are grounded in this paper and cite their sources.
Prolotherapy reinitiates the inflammatory process thereby augmenting the natural healing process of the body by stimulating fibroblastic activity. It is a promising approach in the management of TMDs, especially in refractory cases where conservative management has failed and in patients where surgical management is not possible. The osmotic agent used is dextrose. It produces a hypertonic extracellular environment causing lysis of adjacent cell walls resulting in migration of the macrophages and granulocytes to the area, thus initiating the process of localized inflammation and fibrous healing.
No takes yet. Share an insight, caveat, or question.
Jeelani et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: